← All Celldex Therapeutics, INC filings

Celldex Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CLDX
Celldex Therapeutics, INC
10-K: Celldex Therapeutics 2025 Annual Report Highlights Clinical Progress & Executive Compensation
Celldex Therapeutics' 2025 annual report details significant clinical advancements for Barzolvolimab and CDX-622, alongside executive compensation updates and financial performance.
NASDAQ
CLDX
Celldex Therapeutics, INC
10-K: Celldex Therapeutics Reports Full Year 2024 Results, Highlights Progress in Mast Cell Biology Pipeline
Celldex Therapeutics' 10-K filing summarizes the company's focus on developing therapeutic antibodies for inflammatory, allergic, and autoimmune diseases, with key updates on its clinical programs and financial status.
NASDAQ
CLDX
Celldex Therapeutics, INC
10-K: Celldex Therapeutics Reports Positive Phase 2 Results, Plans Phase 3 Trials
Celldex Therapeutics announced positive results from its Phase 2 study of barzolvolimab in chronic spontaneous urticaria and is planning Phase 3 trials.